US pharma major Eli Lilly (NYSE: LLY) has reported positive topline data from its Phase III ATTAIN-MAINTAIN trial, showing that its oral GLP-1 candidate orforglipron helped patients maintain weight ...
The report estimates that out-of-pocket costs for the 10 drugs will fall nearly 50% in 2026 versus 2025 in all 56 stand-alone prescription drug plans in California, Florida, Texas, New York, and ...
Eli Lilly's oral pill helped maintain weight loss in patients switching from its GLP-1 injection, Zepbound, and rival Novo ...
When HCA Healthcare, one of the largest hospital systems in the U.S., recently told employees it would stop covering blockbuster obesity drugs Zepbound and Wegovy next year, it pointed them to an ...
In topline results of the ATTAIN-MAINTAIN trial, people who lost weight with an injectable GLP-1 were able to keep weight off when switched to an oral GLP-1, Eli Lilly announced.For ATTAIN-MAINTAIN, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback